Critical von Willebrand factor A1 domain residues influence type VI collagen binding

• Published in: Journal of thrombosis and haemostasis Vol. 10; no. 7; pp. 1417 - 1424
• Main Authors: FLOOD, V. H., GILL, J. C., CHRISTOPHERSON, P. A., BELLISSIMO, D. B., FRIEDMAN, K. D., HABERICHTER, S. L., LENTZ, S. R., MONTGOMERY, R. R.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.07.2012; Elsevier Limited
• Subjects: Case-Control Studies; Collagen; Collagen Type VI - metabolism; Female; gene mutation; Humans; Male; Models, Molecular; Mutation; Pedigree; Protein Binding; Recombinant Proteins - chemistry; Recombinant Proteins - genetics; Recombinant Proteins - metabolism; type VI collagen; von Willebrand disease; von Willebrand factor; von Willebrand Factor - chemistry; von Willebrand Factor - genetics; von Willebrand Factor - metabolism
• ISSN: 1538-7933; 1538-7836; 1538-7836
• DOI: 10.1111/j.1538-7836.2012.04746.x

Background:  von Willebrand factor (VWF) binds to subendothelial collagen at sites of vascular injury. Laboratory testing for von Willebrand disease (VWD), however, does not always include collagen binding assays (VWF:CB) and standard VWF:CB assays use type I and/or type III collagen rather than type VI collagen. Objectives:  We report here on several mutations that exclusively alter binding to type VI collagen. Patients/methods:  Healthy controls and index cases from the Zimmerman Program for the Molecular and Clinical Biology of VWD were analyzed for VWF antigen (VWF:Ag), VWF ristocetin cofactor activity and VWF:CB with types I, III and VI collagen. VWF gene sequencing was performed for all subjects. Results:  Two healthy controls and one type 1 VWD subject were heterozygous for an A1 domain sequence variation, R1399H, and displayed a selective decreased binding to type VI collagen but not types I and III. Expression of recombinant 1399H VWF resulted in absent binding to type VI collagen. Two other VWF A1 domain mutations, S1387I and Q1402P, displayed diminished binding to type VI collagen. An 11 amino acid deletion in the A1 domain also abrogated binding to type VI collagen. Conclusions:  VWF:CB may be useful in diagnosis of VWD, as a decreased VWF:CB/VWF:Ag ratio may reflect specific loss of collagen binding ability. Mutations that exclusively affect type VI collagen binding may be associated with bleeding, yet missed by current VWF testing.